IL36G and lymphoma: For example, a Phase 1 trial investigates (NCT03739931) intra-tumoral injection of mRNA-2752 encoding three cytokines OX40L/IL23/IL36γ along with anti-PD-L1 antibody durvalumab in patients with solid tumors or lymphoma.